Global Strategic Insights are manually curated Competitive Intelligence reports for CEOs and Company Heads — which help them track their competition in the Easiest and Shortest way possible.

1. Global Strategic Insights
— Pharmaceuticals
December 2, 2013
© Indalytics Advisors Pvt. Ltd.
www.agmaa.com
info@agmaa.com

2. Global Strategic Insights — Pharmaceuticals — Sample
T ABLE OF C ONTENTS
Activities by Major Players
New Investments in global pharmaceutical space
Strategies
Collaboration
Regulatory News
www.agmaa.com
1

3. Global Strategic Insights — Pharmaceuticals — Sample
A CTIVITIES BY M AJOR P LAYERS
N EW I NVESTMENTS
IN GLOBAL PHARMACEUTICAL SPACE
Cancer Research UK (CRUK) is planning to invest more than GBP100 million
(US$163 million) across 15 research centers in the UK. The centers, as a
part of CRUK’s objective of creating a nationwide network of research
centers, will work in the field of conducting research and providing medical
expertise to cancer patients across the UK.
GlaxoSmithKline (GSK) is planning to invest approximately £25 million
(US$41 million) in Scotland’s pharmaceutical market. The investment is
aimed at starting production of four new pharmaceutical products at GSK’s
facility in Montrose.
The investment will further provide 25 new jobs for process technicians,
engineers and chemists — taking the total of GSK workforce in Scotland to
more than 750.
S TRA TEGIES
Swiss drugmaker Novartis AG, in order to improve shareholders’ value,
and has started a US$5billion share buyback program. The company will
be allocating capital for buyback over a two–year period, and will also be
less involved in acquisitions.
www.agmaa.com
2

4. Global Strategic Insights — Pharmaceuticals — Sample
GlaxoSmithKline is reducing its stake in South Africa's Aspen Pharmacare.
GSK will sell 28.2 million of its total 84.7 million shares in Aspen, for
approximately ZAR7.06 billion (US$690 million). Post the sale, GSK will
retain a seat in Aspen’s board, and will not go for any other sale for a period
of six months from completion of sale. It will use the sale proceeds for
general corporate purposes.
C OLLABORATION
GlaxoSmithKline is collaborating with Pfizer to jointly test a combination
of their respective melanoma compounds. As per the collaboration, the
companies will jointly test the efficacy and safety of Pfizer's investigational
drug palbociclib, a well as GlaxoSmithKline's Mekinist (trametinib) —
which is already in the market. The joint trials will also ascertain the effect
of trying both the medicines on tumor biomarkers, safety and anti-cancer
activity in patients with BRAFV600 wild type melanoma.
The two companies will collaborate on the study, which GSK will conduct.
Financial terms of the agreement have not been disclosed.
Dutch multinational Royal DSM, is pinning off its pharmaceuticals division,
and collaborating with US private equity firm JLL Partners to setup a new
company. As per the collaboration, the new entity will have Royal DSM’s
Pharmaceutical Products division (DPP), along with the service company —
Patheon — from JLL’s portfolio. The company will work as a global contract
development
www.agmaa.com
and
manufacturing
organization
(CDMO)
for
the
3

5. Global Strategic Insights — Pharmaceuticals — Sample
pharmaceutical industry. JLL will have 51% stake in the new company, with
49% stake with Royal DSM.
R EGULATORY N EWS
Nexavar (Sorafenib) — a cancer drug co–developed and co–marketed by
Bayer and Onyx Pharmaceuticals — has receive approval from the US Food
and Drug Administration (FDA).
As per the approval, Nexavar can now be used for the treatment of
metastatic differentiated thyroid carcinoma that cannot be treated with
radioactive iodine and is progressing. The approval was based on a review
by FDA that Nexavar extended progression–free survival by 41%,
compared to placebo.
FDA is also removing certain restrictions from GlaxoSmithKline's diabetes
drug — Avandia (rosiglitazone). The drug was linked to cardiovascular
problems through a meta–analysis in 2007, and was banned in both the US
and Europe.
FDA has now acted on results of a record trial, which depicted that patients
treated with Avandia, do not have increased risk of heart attack or death,
as compared to those treated with metformin and sulphonylurea.
www.agmaa.com
4

6. Global Strategic Insights — Pharmaceuticals — Sample
W HAT IS G LOBAL S TRATEGIC I NSIGHTS ?
At Agmaa, we have worked with many of the Fortune 500 executives, and
have identified the following common concerns with them:
92%
of the CEOs and company heads
don’t’ have time to update themselves with
latest activities of their competitors.
80% of the CEOs and company heads
have less than 15 minutes every week, to
track their respective sectors.
75% of the CEOs and company heads need
ready–to–consume updates on their
competitors and their sector, right before
their meetings and presentations.
www.agmaa.com
5

7. Global Strategic Insights — Pharmaceuticals — Sample
Based on the client feedback and our extensive experience, we have
designed Global Strategic Insights as an easy–to–decipher report. The
competitive intelligence report helps our readers with:
The report is written specifically for CEOs
and company heads — to help them take
accurate and timely decisions, and not miss–
out on any trend.
Each competitor news is manually curated —
to be communicate in less than 100 words.
The whole report can be read in less than 10
minutes.
The activities are clubbed under trends — to
help readers easily assimilate and recall
them.
The reports are published as PDF — to
enable easy storage.
In order to subscribe to Global Strategic Insights, please visit
www.gsi.agmaa.com or mail us at gsi@agmaa.com.
www.agmaa.com
6